|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.350 SEK | +0.75% |
|
+4.17% | +46.10% |
| 05-22 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 05-15 | Sweden's Intervacc Elects New Chair | MT |
Company Valuation: Intervacc AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,669 | 1,313 | 479.4 | 88.61 | 314.9 | 460.1 | - | - |
| Change | - | -50.81% | -63.48% | -81.52% | 255.38% | 46.1% | - | - |
| Enterprise Value (EV) 1 | 2,553 | 1,267 | 391.2 | 54.31 | 154 | 373.1 | 364.1 | 460.1 |
| Change | - | -50.36% | -69.13% | -86.12% | 183.58% | 142.24% | -2.41% | 26.37% |
| P/E Ratio | -90.2x | -20.3x | -3.75x | -1.17x | -3.42x | -5.63x | -5.63x | -10.4x |
| PBR | 8.66x | 5.25x | 2.01x | 0.55x | 1x | 2.37x | 2.29x | - |
| PEG | - | -0x | -0.1x | 0x | 0x | 0.5x | - | 0.2x |
| Capitalization / Revenue | 509x | 136x | 59.8x | 7.52x | 15.7x | 28.8x | 15.3x | 2.81x |
| EV / Revenue | 487x | 131x | 48.8x | 4.61x | 7.67x | 23.3x | 12.1x | 2.81x |
| EV / EBITDA | -110x | -29.1x | -5.67x | -0.92x | -3.27x | -5.83x | -5.6x | -19.2x |
| EV / EBIT | -86.9x | -19.7x | -4.18x | -0.7x | -1.84x | -4.5x | -4.33x | -10.7x |
| EV / FCF | -53.3x | -16.7x | -8.16x | -1.01x | -2.3x | -5.04x | -4.5x | -7.08x |
| FCF Yield | -1.88% | -5.99% | -12.3% | -99.2% | -43.4% | -19.8% | -22.2% | -14.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.59 | -1.28 | -1.69 | -1 | -0.27 | -0.24 | -0.24 | -0.13 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.241 | 9.684 | 8.015 | 11.79 | 20.09 | 16 | 30 | 164 |
| EBITDA 1 | -23.24 | -43.56 | -68.98 | -58.75 | -47.09 | -64 | -65 | -24 |
| EBIT 1 | -29.39 | -64.41 | -93.58 | -77.28 | -83.5 | -83 | -84 | -43 |
| Net income 1 | -29.38 | -64.16 | -102.9 | -75.52 | -80.82 | -81.6 | -83.3 | - |
| Net Debt 1 | -115.5 | -45.52 | -88.2 | -34.3 | -160.9 | -87 | -96 | - |
| Reference price 2 | 53.200 | 26.000 | 6.330 | 1.170 | 0.924 | 1.350 | 1.350 | 1.350 |
| Nbr of stocks (in thousands) | 50,160 | 50,491 | 75,736 | 75,736 | 340,813 | 340,813 | - | - |
| Announcement Date | 18/02/22 | 17/02/23 | 16/02/24 | 13/02/25 | 17/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.63x | 23.32x | -5.83x | - | 48.96M | |
| 33.17x | 8.64x | 26.13x | 0.05% | 56.42B | |
| 16.69x | 5.03x | 10.91x | 1.8% | 44.54B | |
| -17.8x | 4.17x | -7.3x | -.--% | 22.9B | |
| -36.36x | 12.23x | -35.67x | -.--% | 21.21B | |
| 20.25x | 3.95x | 10.26x | -.--% | 16.4B | |
| 21.44x | 4.3x | 14.23x | -.--% | 15.4B | |
| 16.8x | 4.85x | 11.36x | -.--% | 13.35B | |
| -433.48x | 29.5x | -3289.39x | -.--% | 12.36B | |
| 36.9x | 14.16x | 41.61x | 0.18% | 11.15B | |
| Average | -34.80x | 11.02x | -322.37x | 0.23% | 21.38B | |
| Weighted average by Cap. | -12.26x | 8.35x | -180.58x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IVACC Stock
- Valuation Intervacc AB
Select your edition
All financial news and data tailored to specific country editions
